Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by First Light Asset Management LLC

Share on StockTwits

First Light Asset Management LLC lessened its position in Omnicell, Inc. (NASDAQ:OMCL) by 36.5% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 331,462 shares of the company’s stock after selling 190,587 shares during the period. Omnicell makes up about 4.0% of First Light Asset Management LLC’s holdings, making the stock its 6th largest position. First Light Asset Management LLC’s holdings in Omnicell were worth $28,516,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Invesco Ltd. boosted its stake in Omnicell by 79.8% during the 2nd quarter. Invesco Ltd. now owns 779,632 shares of the company’s stock valued at $67,072,000 after purchasing an additional 346,029 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Omnicell by 5.7% during the 2nd quarter. BlackRock Inc. now owns 6,413,649 shares of the company’s stock valued at $551,764,000 after buying an additional 344,744 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of Omnicell by 709.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 231,236 shares of the company’s stock valued at $18,694,000 after buying an additional 202,682 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Omnicell by 716.6% during the 1st quarter. JPMorgan Chase & Co. now owns 225,620 shares of the company’s stock valued at $18,239,000 after buying an additional 197,990 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Omnicell by 4.6% during the 2nd quarter. Vanguard Group Inc. now owns 4,223,552 shares of the company’s stock valued at $363,352,000 after buying an additional 186,781 shares during the period. 98.38% of the stock is owned by hedge funds and other institutional investors.

In other Omnicell news, EVP Dan S. Johnston sold 9,929 shares of the stock in a transaction on Friday, June 28th. The stock was sold at an average price of $85.47, for a total value of $848,631.63. Following the completion of the sale, the executive vice president now owns 31,505 shares in the company, valued at approximately $2,692,732.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Scott Peter Seidelmann sold 1,300 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $75.17, for a total value of $97,721.00. Following the completion of the sale, the executive vice president now owns 26,333 shares of the company’s stock, valued at approximately $1,979,451.61. The disclosure for this sale can be found here. Insiders sold a total of 22,479 shares of company stock valued at $1,746,040 in the last quarter. 2.77% of the stock is currently owned by company insiders.

Shares of Omnicell stock opened at $74.41 on Friday. Omnicell, Inc. has a one year low of $56.96 and a one year high of $92.59. The stock’s fifty day moving average is $71.70 and its 200 day moving average is $78.28. The stock has a market cap of $3.07 billion, a P/E ratio of 48.63, a P/E/G ratio of 2.40 and a beta of 1.13. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.54 and a current ratio of 2.03.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, July 25th. The company reported $0.51 EPS for the quarter, topping the Zacks’ consensus estimate of $0.47 by $0.04. Omnicell had a return on equity of 11.85% and a net margin of 5.70%. The company had revenue of $217.40 million for the quarter, compared to analysts’ expectations of $214.13 million. During the same period last year, the firm earned $0.46 EPS. Omnicell’s revenue for the quarter was up 15.2% compared to the same quarter last year. Analysts predict that Omnicell, Inc. will post 2.05 EPS for the current year.

Several research firms have recently weighed in on OMCL. ValuEngine cut Omnicell from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. Craig Hallum raised Omnicell from a “hold” rating to a “buy” rating and set a $85.00 price target on the stock in a report on Friday, July 26th. BidaskClub cut Omnicell from a “buy” rating to a “hold” rating in a report on Thursday, June 27th. Finally, Zacks Investment Research raised Omnicell from a “hold” rating to a “buy” rating and set a $79.00 price target on the stock in a report on Monday, July 29th. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company. Omnicell currently has an average rating of “Buy” and a consensus price target of $79.11.

Omnicell Company Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Read More: How the Consumer Price Index (CPI) is calculated?

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Turquoise Hill Resources  Upgraded at Macquarie
Turquoise Hill Resources Upgraded at Macquarie
Tyler Technologies  Upgraded to Buy at Zacks Investment Research
Tyler Technologies Upgraded to Buy at Zacks Investment Research
Sanofi  Given a €81.00 Price Target by Goldman Sachs Group Analysts
Sanofi Given a €81.00 Price Target by Goldman Sachs Group Analysts
Valley National Bancorp  Earns Outperform Rating from Analysts at Royal Bank of Canada
Valley National Bancorp Earns Outperform Rating from Analysts at Royal Bank of Canada
Asura Coin  Market Cap Tops $14,736.00
Asura Coin Market Cap Tops $14,736.00
LATOKEN  Trading 2.3% Higher  Over Last 7 Days
LATOKEN Trading 2.3% Higher Over Last 7 Days


© 2006-2019 Ticker Report